Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria - TAfenoquine DOsing REvised

NCT06148792 is registered in ClinicalTrials.gov with Menzies School of Health Research as lead sponsor.

NCT NCT06148792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06148792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria - TAfenoquine DOsing REvised
Lead sponsor
Menzies School of Health Research
Phase
Phase 3
Overall status
Recruiting
Start date
May 10, 2024
Completion date
March 1, 2027
Enrollment
1,090 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

vivax malaria